人工智能在阿尔茨海默病全程管理中的应用进展

doi:10.3969/j.issn.1003-9198.2025.08.003

Abstract

Abstract: This review introduces the advances in the application of artificial intelligence (AI) in the early screening and diagnosis of Alzheimer’s disease (AD), as well as in the intervention and care for AD patients. It highlights that AI can assist in the early diagnosis of AD and the entire drug development process, identify the potential risks of AD, generate personalized treatment plans for AD patients, and more accurately predict the disease outcomes, ultimately improve the quality of life in AD patients. However, AI in the full-course management of AD still faces challenges, including ethical considerations, data privacy, and the seamless integration of AI into clinical workflows.

Key words: Alzheimer’s disease, artificial intelligence, medical imaging, biomarker, disease management

CLC Number:

R749.16

YANG Huijuan, LIU Shunying, SU Jing, ZENG Liting. Advances in the application of artificial intelligence in the full-course management of Alzheimer’s disease[J]. Practical Geriatrics, 2025, 39(8): 768-772.

References

[1] 王刚, 齐金蕾, 刘馨雅,等.中国阿尔茨海默病报告2024[J]. 诊断学理论与实践, 2024, 23(3): 219-256.
[2] PASSERI E, ELKHOURY K, MORSINK M, et al. Alzheimer’s disease: treatment strategies and their limitations[J]. Int J Mol Sci, 2022, 23(22):13954.
[3] SØRENSEN L, IGEL C, HANSEN N L, et al. Early detection of Alzheimer’s disease using MRI hippocampal texture[J]. Hum Brain Mapp, 2016, 37(3): 1148-1161.
[4] DE OLIVEIRA M S, BALTHAZAR M F, D’ABREU A, et al. MR imaging texture analysis of the corpus callosum and thalamus in amnestic mild cognitive impairment and mild Alzheimer disease[J]. AJNR Am J Neuroradiol, 2011, 32(1): 60-66.
[5] JIN D, ZHOU B, HAN Y, et al. Generalizable, reproducible, and neuroscientifically interpretable imaging biomarkers for Alzheimer’s disease[J]. Adv Sci, 2020, 7(14): 2000675.
[6] FALGÀS N, SÁNCHEZ-VALLE R, BARGALLÓ N, et al. Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer’s disease patients: a comparison between visual and quantitative assessment[J]. Neuroimage Clin, 2019, 23: 101927.
[7] GALTON C J, GOMEZ-ANSON B, ANTOUN N, et al. Temporal lobe rating scale: application to Alzheimer’s disease and frontotemporal dementia[J]. J Neurol Neurosurg Psychiatry, 2001, 70(2): 165-173.
[8] FALGÀS N, BALASA M, BARGALLÓ N, et al. Diagnostic accuracy of MRI visual rating scales in the diagnosis of early onset cognitive impairment[J]. J Alzheimers Dis, 2020, 73(4): 1575-1583.
[9] KOIKKALAINEN J R, RHODIUS-MEESTER H F M, FREDERIKSEN K S, et al. Automatically computed rating scales from MRI for patients with cognitive disorders[J]. Eur Radiol, 2019, 29(9):4937-4947.
[10] MÖLLER C, PIJNENBURG Y A L, VAN DER FLIER W M, et al. Alzheimer disease and behavioral variant frontotemporal dementia: automatic classification based on cortical atrophy for single-subject diagnosis[J]. Radiology, 2016, 279(3): 838-848.
[11] HOSSEINI-ASL E, GHAZAL M, MAHMOUD A, er al. Alzheimer’s disease diagnostics by a 3D deeply supervised adaptable convolutional network[J]. Front Biosci: Landmark Ed, 2018, 23(3):584-596.
[12] LIU S, LIU S, CAI W, et al. Multimodal neuroimaging feature learning for multiclass diagnosis of Alzheimer’s disease[J]. IEEE Trans Biomed Eng, 2015, 62(4): 1132-1140.
[13] GRUESO S,VIEJO-SOBERA R. Machine learning methods for predicting progression from mild cognitive impairment to Alzheimer’s disease dementia: a systematic review[J]. Alzheimers Res Ther, 2021, 13(1): 162.
[14] DREW P J. Vascular and neural basis of the BOLD signal[J]. Curr Opin Neurobiol, 2019, 58: 61-69.
[15] JU R, HU C, ZHOU P, et al. Early diagnosis of Alzheimer’s disease based on resting-state brain networks and deep learning[J]. IEEE/ACM Trans Comput Biol Bioinform, 2019, 16(1): 244-257.
[16] MEIER T B, DESPHANDE A S, VERGUN S, et al. Support vector machine classification and characterization of age-related reorganization of functional brain networks[J]. Neuroimage, 2012, 60(1): 601-613.
[17] RAMZAN F, KHAN M U G, REHMAT A, et al. A deep learning approach for automated diagnosis and multi-class classification of Alzheimer’s disease stages using resting-state fMRI and residual neural networks[J]. J Med Syst, 2019, 44(2): 37.
[18] MAYO C D, GARCIA-BARRERA M A, MAZEROLLE E L, et al. Relationship between DTI metrics and cognitive function in Alzheimer’s disease[J].Front Aging Neurosci, 2019, 10:436.
[19] WEE C Y, YAP P T, LI W, et al. Enriched white matter connectivity networks for accurate identification of MCI patients[J]. Neuroimage, 2011, 54(3): 1812-1822.
[20] MARZBAN E N, ELDEIB A M, YASSINE I A, et al. Alzheimer’s disease diagnosis from diffusion tensor images using convolutional neural networks[J]. PLoS One, 2020, 15(3): e0230409.
[21] JACK C R Jr, ANDREWS S J, BEACH T G, et al. Revised criteria for the diagnosis and staging of Alzheimer’s disease[J]. Nat Med, 2024, 30(8): 2121-2124.
[22] SUPPIAH S, DIDIER M A,VINJAMURI S. The who, when, why, and how of PET amyloid imaging in management of Alzheimer’s disease—review of literature and interesting images[J]. Diagnostics, 2019, 9(2): 65.
[23] PAN X, ADEL M, FOSSATI C, et al. Multilevel feature representation of FDG-PET brain images for diagnosing Alzheimer’s disease[J]. IEEE J Biomed Health Inform, 2019, 23(4): 1499-1506.
[24] CHAVES R, RAMÍREZ J, GÓRRIZ J M. Integrating discretization and association rule-based classification for Alzheimer’s disease diagnosis[J]. Expert Syst Appl, 2013, 40(5): 1571-1578.
[25] HOJJATI S H, EBRAHIMZADEH A, KHAZAEE A, et al. Predicting conversion from MCI to AD by integrating rs-fMRI and structural MRI[J]. Comput Biol Med, 2018, 102: 30-39.
[26] ZHU X, SUKH I, SHEN D. A novel matrix-similarity based loss function for joint regression and classification in AD diagnosis[J]. Neuroimage, 2014, 100: 91-105.
[27] JAMES C, RANSON J M, EVERSON R, et al. Performance of machine learning algorithms for predicting progression to dementia in memory clinic patients[J]. JAMA Netw Open, 2021, 4(12): e2136553.
[28] WANG X, JIAO B, LIU H, et al. Machine learning based on Optical Coherence Tomography images as a diagnostic tool for Alzheimer’s disease[J]. CNS Neurosci Ther, 2022, 28(12): 2206-2217.
[29] BADER J M, GEYER P E, MÜLLER J B, et al. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer’s disease[J]. Mol Syst Biol, 2020, 16(6): e9356.
[30] GIORGIO J, JAGUST W J, BAKER S, et al. A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation[J]. Nat Commun, 2022, 13(1): 1887.
[31] 殷潇潇,王思文,王贺,等.语音重复任务在轻度认知功能障碍检测中的应用[J]. 中国神经精神疾病杂志, 2024, 50(4):247-251.
[32] RODRIGUEZ S, HUG C, TODOROV P, et al. Machine learning identifies candidates for drug repurposing in Alzheimer’s disease[J]. Nat Commun, 2021, 12(1): 1033.
[33] XIE C, ZHUANG X X, NIU Z, et al. Amelioration of Alzheimer’s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow[J]. Nat Biomed Eng, 2022, 6(1): 76-93.
[34] YANG X, WANG Y, BYRNE R, et al. Concepts of artificial intelligence for computer-assisted drug discovery[J]. Chem Rev, 2019, 119(18): 10520-10594.
[35] QIU Y,CHENG F. Artificial intelligence for drug discovery and development in Alzheimer’s disease[J]. Curr Opin Struct Biol, 2024, 85: 102776.
[36] KALE M, WANKHEDE N, PAWAR R, et al. AI-driven innovations in Alzheimer’s disease: integrating early diagnosis, personalized treatment, and prognostic modelling[J]. Ageing Res Rev, 2024, 101: 102497.
[37] ANGELUCCI F, AI A R, PIENDEL L, et al. Integrating AI in fighting advancing Alzheimer: diagnosis, prevention, treatment, monitoring, mechanisms, and clinical trials[J]. Curr Opin Struct Biol, 2024, 87: 102857.
[38] SHEEHY L, BOUCHARD S, KAKKAR A, et al. Development and initial testing of an artificial intelligence-based virtual reality companion for people living with dementia in long-term care[J]. J Clin Med, 2024, 13(18): 5574.
[39] RASHID N L A, LEOW Y, KLAININ-YOBAS P, et al. The effectiveness of a therapeutic robot, ‘Paro’, on behavioural and psychological symptoms, medication use, total sleep time and sociability in older adults with dementia: a systematic review and meta-analysis[J]. Int J Nurs Stud, 2023, 145: 104530.
[40] LIVINGSTON G, HUNTLEY J, LIU K Y, et al. Dementia prevention, intervention, and care: 2024 report of the lancet standing commission[J]. Lancet, 2024, 404(10452): 572-628.

Advances in the application of artificial intelligence in the full-course management of Alzheimer’s disease

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	HE Xinxin, XIE Dongmei, WANG Xiaoling, LI Ying, GAO Langli. Research progress in the application of artificial intelligence in the care for disabled elderly [J]. Practical Geriatrics, 2025, 39(8): 757-761.
[2]	JIANG Huizeng, LIU Jinna, ZHANG Dandan, ZHANG Jie. Advances of the application of artificial intelligence in fall risk management in the elderly [J]. Practical Geriatrics, 2025, 39(8): 762-767.
[3]	LUO Linyu, XIE Dongmei, ZHANG Meng, YUE Jirong, LYU Juan. Current applications of artificial intelligence in dysphagia [J]. Practical Geriatrics, 2025, 39(8): 773-777.
[4]	YUAN Pingqiao, LI Zemei, HAN Yao, SUN Zhaoyu. Advances in the application of artificial intelligence in health management in the elderly patients [J]. Practical Geriatrics, 2025, 39(8): 778-781.
[5]	ZHONG Yi, FENG Yue, ZHANG Xinlong, DING Rui, SI Yanna. Research progress in single-cell RNA sequencing for Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(8): 857-861.
[6]	WANG Yang, LI Daiping, YANG Yanwu, HE Bofei, YUE Jirong, DONG Birong, GE Meiling. Current status and prospects of the application of artificial intelligence in geriatric medicine teaching [J]. Practical Geriatrics, 2025, 39(7): 753-756.
[7]	ZHU Xiangyu, HANG Lejia, WANG Yu, WU Yuyi, ZHAO Yijing, ZHU Bei, HUANG Jingjing. Advances in artificial intelligence for cardiovascular disease in the elderly [J]. Practical Geriatrics, 2025, 39(6): 621-625.
[8]	GU Xingyue, GAO Wei, LU Xiang. Advances in the study of enzymatic protein glycosylation in Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(6): 631-635.
[9]	WANG Yun, FU Liping. Significance of retinal structural and functional changes in the diagnosis of Alzheimer’s disease in high-altitude regions [J]. Practical Geriatrics, 2025, 39(5): 461-465.
[10]	GAO Jingyu, WANG Ting, TAN Simin. Research advance of frailty assessment in patients with multiple myeloma [J]. Practical Geriatrics, 2025, 39(5): 534-538.
[11]	ZUO Rui, GU Shuangshuang, WANG Jun. Research progress of exosomes in elderly patients with sepsis: focus on the pathopathological characteristics and clinical challenges in the elderly [J]. Practical Geriatrics, 2025, 39(4): 330-335.
[12]	WANG Yan, XU Jie, GU Xiaoping. Research advances on association between fatty acid metabolism and Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(4): 415-419.
[13]	LIN Xiaoqi, ZHAO Xinjing, WU Yashuang, ZHAO Wei, CHEN Chen, GAO Tianyu, ZHOU Guoyu. Advances of the mechanisms of gender differences in Alzheimer’s disease [J]. Practical Geriatrics, 2025, 39(4): 420-425.
[14]	LIU Xuande, ZHOU Shigong, XU Zhuqin, SHAN Shoujie. Levels and diagnostic value of serum semaphorin 7A in elderly patients with acute coronary syndrome [J]. Practical Geriatrics, 2025, 39(3): 294-297.
[15]	LIU Shu. A review of impact of cognitive reserve on cognitive function [J]. Practical Geriatrics, 2025, 39(3): 308-311.